Search
All Clinical Trials
A listing of 23106 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
3673 - 3684 of 23106
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona +46 locations
Conditions: Multiple Myeloma
Animal Assisted Therapy in Pediatric Dentistry
Recruiting
A prospective randomized trial measuring physiologic biometrics and perceptions of stress during a pediatric dental exam, cleaning, and simulated radiographs with or without a therapy dog present.
Gender:
ALL
Ages:
Between 4 years and 8 years
Trial Updated:
05/22/2025
Locations: General & Oral Health Center, Chapel Hill, North Carolina
Conditions: Anxiety
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Recruiting
The goal of this clinical trial is to improve cancer patient's health, survival, and quality of life by dispelling risk behaviors for Northwestern Memorial Health Care (NMHC) patients who are cancer survivors.
The main question\[s\] STELLAR aims to answer are:
* How best to combine three behavior interventions (physical activity promotion, smoking cessation, obesity treatment) into one treatment.
* Evaluate the reach of the program. We will look at the number, proportion, and representativenes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Northwestern University-Feinberg School of Medicine, Chicago, Illinois
Conditions: Obesity, Smoking Cessation, Physical Inactivity
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Recruiting
The goal of the Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study is to collect safety and performance data on the commercially available Shoulder iD™ Primary Reversed Glenoid device. The study will learn about standard device use in adult patients who have a functional deltoid muscle and massive and non-repairable rotator cuff tear. The main questions it aims to answer are:
* What is the average improvement in patient-reported shoulder function after 2 years when compared to before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: UCSF, San Francisco, California +7 locations
Conditions: Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Fracture, Humeral, Traumatic Arthritis of Right Shoulder Region (Diagnosis), Shoulder Deformity
Characterization of the Central and Peripheral Wavefront Aberration Profile in Pediatric Myopic Subjects
Recruiting
This is a 3-visit, single site, observational clinical study to evaluate the characterization of the central and peripheral wavefront aberration profiles in pediatric myopic subjects.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/22/2025
Locations: University of Houston College of Optometry - J. Armistead Bldg Room 2195, Houston, Texas
Conditions: Myopia
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/22/2025
Locations: MD First Research - Chandler, Chandler, Arizona +203 locations
Conditions: Alzheimer Disease, Early Onset
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Recruiting
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/22/2025
Locations: Arizona Neuroscience Research, Phoenix, Arizona +39 locations
Conditions: Focal Onset Seizure
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Recruiting
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Accel Research Sites - Achieve Clinical Research, Birmingham, Alabama +282 locations
Conditions: Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/22/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +32 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas +126 locations
Conditions: Arthritis, Psoriatic
Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders
Recruiting
Our Practice Advisory (OPA) are essential tools in clinical decision-making. The alerts are designed to guide providers towards evidence-based practices and improve patient outcomes. The focus of this initiative is on Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) testing, with the goal of addressing unnecessary repeat testing within a 30-day timeframe, which rarely yields significant new insights. Although randomization occurs at the patient level, the primary outcome of this study... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: UCLA Health System, Los Angeles, California
Conditions: Physician Workflow, Resource Utilization
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Recruiting
Background:
For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA. Researchers want to see if the drug pegvisomant can help.
Objective:
To test the role of pegvisomant in children and adolescents with gigantism.
Eligibility:
People ages 2-18 with GH excess for whom usual treatments have not worked or who are not eliginle for them
Design:
Participants... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
05/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pituitary Disease
3673 - 3684 of 23106